UNSPSC 51242204: Antipyrine/hydrocortisone/neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.

UNSPSC 51242204 Antipyrine/hydrocortisone/neomycin/polymyxin b is a Commodity code representing branded and generic ear-drop pharmaceutical products that state and local health departments, hospitals, clinics, and correctional facilities source through cooperative purchasing agreements and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses this code within broader generic multi-source pharmaceutical procurement vehicles that span OTC and prescription products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. MMCAP serves as the primary identified issuing body for recent activity under this code, leveraging three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencala, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) to deliver awarded products. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers, and carry comprehensive insurance including $5,000,000 in commercial general liability, $2,000,000 in network security and privacy liability, and $2,000,000 in professional liability.

MMCAP posted a Request for Proposal on January 20, 2026 (S1070000015802, MMCAP Generic Multi Source Pharmaceuticals and OTC Products) with a proposal due date of March 26, 2026 and a contract effective date of July 1, 2026. The RFP evaluates proposals on price competitiveness (75 percent weighting), fixed pricing for the contract term (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors must have products available in the marketplace by May 15, 2026, and the contract term spans two years for new responders with optional MMCAP extensions, while incumbent amendments align through June 30, 2028. MMCAP reserves sole, dual, or multi-award authority based on therapeutic considerations, product availability, patient safety, and member-specific needs. No specific dollar values, set-aside designations, or disadvantaged-enterprise restrictions appear in the available documentation.